Elanco Animal Health Incorporated (ELAN) Joins S&P MidCap 400 Following Strong Q2 Growth and Product Ramp-Up

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Elanco Animal Health Incorporated is one of them.

Elanco Animal Health Incorporated (NYSE:ELAN), a global leader in veterinary pharmaceuticals and biologics, continues to advance its mission of improving animal health and food safety through innovation and sustainability. Serving veterinarians, farmers, and pet owners worldwide, the company leverages nearly 70 years of expertise to deliver solutions for companion animals and livestock.

In September 2025, Elanco Animal Health Incorporated (NYSE:ELAN) joined the S&P MidCap 400 Index, reflecting rising investor confidence and market profile. The company exceeded expectations in Q2 2025, reporting double-digit organic growth, a successful ramp-up of new products, and upwardly revised full-year guidance. Aggressive deleveraging of the balance sheet has enhanced financial flexibility for upcoming product launches and strategic investments.

Recent regulatory approvals have expanded the corporation’s product portfolio. Zenrelia™ (ilunocitinib), a once-daily oral JAK inhibitor for canine dermatology, treats pruritus and atopic dermatitis, showing superior safety and efficacy in early EU studies and making it the company’s fastest-growing brand. The USDA-approved TruCan™ Ultra CIV H3N2/H3N8 vaccine provides broad respiratory protection for dogs, while expanded access to the Canine Parvovirus Monoclonal Antibody (CPMA), including a $3M donation to clinics and shelters, underscores the firm’s commitment to public health.

Elanco Animal Health Incorporated (NYSE:ELAN)’s innovation pipeline positions the company for continued growth, with six potential blockbuster products expected in the US by year-end, spanning monoclonal antibodies, advanced vaccines, and oral therapies.

While we acknowledge the potential of ELAN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.